Richard Lottenberg is a notable inventor based in Gainesville, FL (US). He has made significant contributions to the field of thrombolytic therapy, with a focus on bacterial plasmin receptors. His innovative work has led to the development of novel methods and compositions that enhance fibrinolytic activity.

Latest Patents

Lottenberg holds 3 patents, with his latest invention concerning bacterial plasmin receptors as fibrinolytic agents. This invention details a receptor with a high affinity for plasmin, which has been characterized, purified, cloned, and expressed. The receptor can be utilized in combination therapies, administered prior to, concurrently with, or after a plasminogen activator. Furthermore, it can be bound to plasmin and administered to humans or animals requiring fibrinolytic activity. Additionally, the invention includes a novel immobilized form of plasmin that accumulates at the site where antifibrinolytic activity is needed.

Career Highlights

Lottenberg is affiliated with the University of Florida Research Foundation, Incorporated. His work has been instrumental in advancing therapeutic options for patients in need of thrombolytic treatments.

Collaborations

Some of his notable coworkers include Michael D Boyle and Christopher C Broder. Their collaborative efforts have contributed to the success of his research and innovations.

Conclusion

Richard Lottenberg's contributions to thrombolytic therapy through his innovative patents highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in medical treatments.